Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2018.0273
FOCUS
|
Recent approval of new targeted drugs for non-metastatic cancers improves oncological outcomes.
|
Demosthenes Ziogas, MD, PhD 1, 2.
|
Affiliation: Demosthenes Ziogas MD, PhD,
1Department of Surgery, 'G. Hatzikosta' General Hospital, Ioannina 45001, Greece
2Centre for Biosystems and Synthetic Genomic Network Medicine Center – CBS.GenNetMed Ioannina University, Ioannina, Greece. omega replica watches
E-mail: deziogas@hotmail.com
|
Abstract
Recent positive randomized clinical trials with approval of the new targeted drugs in the adjuvant setting can improve survival or even cure rates for some cancer-specific types. However, no adjuvant targeted therapy has been developed for many other major cancers. Challenges and solutions with personalized genome analysis are described.
(Citation: Gastric & Breast Cancer 2018; 13(1): 37-42)
|
|
| You can have an online full-text access and a PDF of this article: |
- Either purchase this paper for €35 EUR. Please, click here
|
|
- Or through one year subscription PayPal
|
|
